Filer Snapshot

JOHNSON & JOHNSON

CIK 0000200406. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

3,341

Latest filing

27 May 2026

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q1 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13F portfolio Save page

Latest 13F portfolio

$652.36M

16 holdings for Q1 2026

Open portfolio

Largest parsed holding

PTGX

$258.14M reported value

Open holding

13D/G large stake

RLYB

31 Mar 2026 · 2.9% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC filing SD

SD filed on 27 May 2026 for CIK 0000200406.

View Source Filing
Identity
Public symbols
JNJ on NYSE
Industry
Pharmaceutical Preparations (Office Of Life Sciences)
Business address
One Johnson & Johnson Plz, New Brunswick, NJ, 08933
SEC ownership signals
Parsed ownership coverage

13F reported value

$652.36M

Latest parsed Form 13F reported market value.

Form 3/4/5 holdings value

$4.3B

Estimated from parsed insider ownership filings when values are available.

Largest 13F symbols

PTGX, NBTX, MGTX, RAPP

Largest symbols in the latest parsed Form 13F holdings.

Top disclosed positions
KVUE MGTX CVRX CTNM
Largest 13F holdings
PTGX NBTX MGTX RAPP CVRX CTNM LEGN XNCR
+8 morePRCT FATE NMRA RLYB VOR LAB NNOX ACET
Schedule 13G stakes
RAPP CVRX RLYB
SEC record
State of incorporation
NJ
Fiscal year end
03 January
Former names
JOHNSON & JOHNSON ET AL (to 23 Jan 1996)

Filer intelligence

What SEC filings say about JOHNSON & JOHNSON

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Open 13F portfolio Save filer

Quick read

  • Latest parsed 13F shows $652.36M across 16 reported holdings for Q1 2026.
  • Largest parsed 13F holding: PTGX at $258.14M.
  • 3 recent 13D/G stake rows found; top row is RLYB at 2.9% ownership.
  • Forms 3/4/5 show insider context for KVUE worth $4.19B.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 16 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 3 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 4 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q1 2026 - 13 May 2026

Top 5 concentration

89%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$583.18M

Compared with $652.36M total 13F value.

Top 5 net change

$0

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: RLYB · Largest trim: RLYB

PTGX NBTX MGTX RAPP CVRX Other holdings

PTGX

39.6%

Protagonist Therapeutics Inc.

$258.14M

NBTX

26.6%

Nanobiotix S.A.

$173.61M

MGTX

8.8%

MeiraGTx Holdings plc

$57.51M

RAPP

8.6%

Rapport Therapeutics, Inc.

$55.84M

CVRX

5.8%

CVRx, Inc.

$38.08M

13D/G large-stake context

RLYB

31 Mar 2026 · Common Stock, $0.0001 par value

2.9%
Issuer page 13D/G history

CVRX

31 Dec 2025 · Common Stock, $0.01 par value

15%
Issuer page 13D/G history

RAPP

30 Sep 2025 · Common Stock, $0.001 par value

4.9%
Issuer page 13D/G history

Forms 3/4/5 insider context

KVUE

23 Aug 2023 · 10% owner

$4.19B
Issuer page Owner page

MGTX

09 Nov 2022 · 10% owner

$42.24M
Issuer page Owner page

CVRX

26 Nov 2025 · 10% owner

$40.37M
Issuer page Owner page

CTNM

09 Apr 2024 · 10% owner

$33.74M
Issuer page Owner page

Latest update

What changed recently for JOHNSON & JOHNSON

New filing available

Latest 13F period: Q1 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

13 May 2026

Page type

Filer profile

Latest period

Q1 2026

Institutional portfolio context was refreshed from a 13F filing filed on 13 May 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

JOHNSON & JOHNSON has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest 13F period: Q1 2026. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 22 Apr 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0000200406 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
3,341
First seen
10 Mar 1994
Latest filing
27 May 2026
Entity
Company

Observed form types

SD 13F-HR 4 SCHEDULE 13G 8-K 10-Q SCHEDULE 13G/A 13F-HR/A ARS DEFA14A +35 more

Primary evidence

Open SEC filing index JOHNSON & JOHNSON SEC filings JOHNSON & JOHNSON 13F portfolio JOHNSON & JOHNSON 13D/G history JOHNSON & JOHNSON owner filings

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 1,000 SEC filings for JOHNSON & JOHNSON.

Open full filing history
SD File 001-03215

SD

Filing date
27 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR File 028-20072

13F-HR filing

Filing date
13 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
04 May 2026
Reporting date
01 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G File 005-12802

SCHEDULE 13G filing

Filing date
01 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
27 Apr 2026
Reporting date
23 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
27 Apr 2026
Reporting date
23 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
27 Apr 2026
Reporting date
23 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
27 Apr 2026
Reporting date
23 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
27 Apr 2026
Reporting date
23 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
27 Apr 2026
Reporting date
23 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4

Filing date
27 Apr 2026
Reporting date
23 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .